Fig. 1: Humoral immune response after rAd5 and rAd19a boost. | npj Vaccines

Fig. 1: Humoral immune response after rAd5 and rAd19a boost.

From: Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus

Fig. 1

a BALB/c mice were primed intramuscularly with an F-encoding DNA plasmid (10 µg plasmid) followed by electroporation and boosted 28 days later either intramuscularly (i.m.) or intranasally (i.n.) with rAd5 or rAd19a viral vectors encoding for F (2 ×106 infectious units per vector). Serum antibody responses were analysed 14 days and mucosal immune responses 36 days after boost immunization. F-specific IgG (b and c) and IgA (d) were examined by a flow cytometric assay using a 293A cell line stably expressing F. For IgG arbitrary units were calculated according to standard mouse serum and mean fluorescence intensities (MFI) were shown for IgA. The MFI of naïve samples indicate the background values of the assay. Bars represent mean values with +SEM (Serum: rAd5 (i.n.) n = 11, rAd19 (i.n.) n = 12, other groups n = 18; BALF: rAd5 (i.n.) n = 11, other groups n = 12). e Neutralization antibodies against RSV in sera were analysed by microneutralization assay 14 days after boost immunization. Depicted are the individual PRNT50 values with the group´s mean values with ±SEM. (naive n = 6, rAd5 (i.n.) n = 11, rAd19 (i.n.) n = 12, other groups n = 18). Data were analysed by one-way ANOVA followed by Tukey´s multiple comparison test. Statistically significant differences were indicated among all groups (*p < 0.05; **p < 0.005; ****p < 0.0001).

Back to article page